Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24724337 | 0.86 | F2RL1 (0.36) | DGAT1F2RL1NPC1 | |
| SCHEMBL24667775 | 0.81 | DGAT1 (0.40) | DGAT1F2RL1NPC1 | |
| SCHEMBL29109010 | 0.78 | KDM4E (0.34) | DGAT1F2RL1NPC1 | |
| SCHEMBL30827496 | 0.75 | NPC1 (0.37) | DGAT1F2RL1NPC1 | |
| SCHEMBL22393670 | 0.75 | NPC1 (0.37) | DGAT1F2RL1NPC1 | |
| SCHEMBL24724344 | 0.73 | KMT2A (0.38) | DGAT1NPC1 | |
| SCHEMBL24724717 | 0.71 | DUT (0.35) | DGAT1NPC1 | |
| SCHEMBL3957728 | 0.71 | NPC1 (0.37) | DGAT1F2RL1NPC1 | |
| SCHEMBL30003147 | 0.69 | KMT2A (0.34) | DGAT1NPC1 | |
| SCHEMBL25072469 | 0.69 | NPC1 (0.33) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-4347590-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715909-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | DGAT1 3312/4885F2RL1 3926/4885NPC1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.